Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the beta cell.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.Clinical and experimental immunology · 2010
   Guideline
2. DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes.Diabetes · 2015
   Article
3. Analysis of peri-islet CD45-positive leucocytic infiltrates in long-standing type 1 diabetic patients.Diabetologia · 2015
   Article
4. Type 1 diabetes: A predictable disease.World journal of diabetes · 2015
   Review
5. The streetlight effect in type 1 diabetes.Diabetes · 2015
   Review
6. Invasive procedures with questionable indications.Annals of medicine and surgery (2012) · 2014
   Article
7. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.Rheumatic diseases clinics of North America · 2014
   Review
8. New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation.Current diabetes reports · 2014
   Review
9. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings.Pediatric diabetes · 2014
   Review
10. Dimorphic histopathology of long-standing childhood-onset diabetes.Diabetologia · 2010
    Article
11. Islet inflammation and CXCL10 in recent-onset type 1 diabetes.Clinical and experimental immunology · 2010
    Article
12. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.Nature reviews. Immunology · 2010
    Review
13. Histopathology of type 1 diabetes: old paradigms and new insights.The review of diabetic studies : RDS · 2009
    Article

Corrections and comments

• Comment on
  Analysis of islet inflammation in human type 1 diabetes.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as